Open Access
CC BY 4.0 · Endosc Int Open 2025; 13: a27331229
DOI: 10.1055/a-2733-1229
Original article

Clinical feasibility of gastric endoscopic submucosal dissection in patients on glucocorticoids or immunomodulators: Propensity-score-matched study

Authors

  • Hiroki Fukuya

    1   Department of Gastroenterology, National Hospital Organisation Kyushu Medical Center, Fukuoka, Japan (Ringgold ID: RIN37085)
    2   Institute of Research Center, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan
  • Eikichi Ihara

    3   Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan (Ringgold ID: RIN12923)
  • Yoichiro Iboshi

    1   Department of Gastroenterology, National Hospital Organisation Kyushu Medical Center, Fukuoka, Japan (Ringgold ID: RIN37085)
    2   Institute of Research Center, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan
  • Yorinobu Sumida

    4   Department of Gastroenterology, Kitakyushu Municipal Medical Center, Fukuoka, Japan
  • Daisuke Yoshimura

    1   Department of Gastroenterology, National Hospital Organisation Kyushu Medical Center, Fukuoka, Japan (Ringgold ID: RIN37085)
    2   Institute of Research Center, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan
  • Shohei Hamada

    1   Department of Gastroenterology, National Hospital Organisation Kyushu Medical Center, Fukuoka, Japan (Ringgold ID: RIN37085)
    2   Institute of Research Center, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan
  • Taisuke Sasaki

    1   Department of Gastroenterology, National Hospital Organisation Kyushu Medical Center, Fukuoka, Japan (Ringgold ID: RIN37085)
    2   Institute of Research Center, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan
  • Akito Ohkubo

    1   Department of Gastroenterology, National Hospital Organisation Kyushu Medical Center, Fukuoka, Japan (Ringgold ID: RIN37085)
    2   Institute of Research Center, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan
  • Shuichi Itonaga

    1   Department of Gastroenterology, National Hospital Organisation Kyushu Medical Center, Fukuoka, Japan (Ringgold ID: RIN37085)
    2   Institute of Research Center, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan
  • Hitoshi Homma

    1   Department of Gastroenterology, National Hospital Organisation Kyushu Medical Center, Fukuoka, Japan (Ringgold ID: RIN37085)
    2   Institute of Research Center, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan
  • Ryota Okitsu

    1   Department of Gastroenterology, National Hospital Organisation Kyushu Medical Center, Fukuoka, Japan (Ringgold ID: RIN37085)
    2   Institute of Research Center, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan
  • Akihisa Ohno

    5   Faculty of Medicine, Graduate School of Medical Sciences, School of Medicine, Department of Medicine and Bioregulatory Science, Kyushu University, Fukuoka, Japan (Ringgold ID: RIN38305)
  • Mitsuru Esaki

    5   Faculty of Medicine, Graduate School of Medical Sciences, School of Medicine, Department of Medicine and Bioregulatory Science, Kyushu University, Fukuoka, Japan (Ringgold ID: RIN38305)
  • Naohiko Harada

    1   Department of Gastroenterology, National Hospital Organisation Kyushu Medical Center, Fukuoka, Japan (Ringgold ID: RIN37085)
    2   Institute of Research Center, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan

Abstract

Background and study aims

Evidence on gastric endoscopic submucosal dissection (ESD) under glucocorticoids or immunomodulators (GC/IM) is limited. We evaluated whether GC/IM use affects gastric ESD outcomes.

Patients and methods

We retrospectively analyzed 411 consecutive ESDs (April 2017-April 2022). GC/IM users (n = 32) were compared with controls (n = 379); 1:3 propensity-score matching yielded 27 vs 81 patients. The primary outcome was overall complications, defined as a composite of pain, fever, delayed bleeding, and delayed perforation. Secondary outcomes were each component, intra-procedure perforation, hospital stay, and use of symptom-directed treatments (analgesics, antipyretics, antibiotics).

Results

Overall complications were more frequent with GC/IM than controls (44.4% vs 21.0%; P = 0.024; relative risk [RR] 2.11, 95% confidence interval 1.16–3.84), driven by pain (40.7% vs 18.5%; P = 0.035) and fever (11.1% vs 1.2%; P = 0.047). Rates of major complications did not differ (delayed bleeding 3.7% vs 2.5%; delayed perforation 0% vs 0%). Intra-procedure perforation was numerically higher (7.4% vs 3.7%) without significance. Median (interquartile range) hospital stay showed a small, non-significant difference (9 [7–12] vs 8 [7–9] days; P = 0.064). Symptom management was used more often with GC/IM (analgesics 25.9% vs 3.7%, P = 0.002; antipyretics 7.4% vs 2.5%, P = 0.270; antibiotics 7.4% vs 3.7%, P = 0.597).

Conclusions

In patients receiving GC/IM, gastric ESD was associated with a higher incidence of minor, clinically managed events—chiefly pain and transient fever—whereas major complications remained uncommon. With close monitoring and prompt symptom-directed care, gastric ESD appeared clinically feasible, albeit with slightly greater resource use and observation time.



Publication History

Received: 07 May 2025

Accepted after revision: 21 October 2025

Accepted Manuscript online:
27 October 2025

Article published online:
11 November 2025

© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/).

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

Bibliographical Record
Hiroki Fukuya, Eikichi Ihara, Yoichiro Iboshi, Yorinobu Sumida, Daisuke Yoshimura, Shohei Hamada, Taisuke Sasaki, Akito Ohkubo, Shuichi Itonaga, Hitoshi Homma, Ryota Okitsu, Akihisa Ohno, Mitsuru Esaki, Naohiko Harada. Clinical feasibility of gastric endoscopic submucosal dissection in patients on glucocorticoids or immunomodulators: Propensity-score-matched study. Endosc Int Open 2025; 13: a27331229.
DOI: 10.1055/a-2733-1229
 
  • References

  • 1 Ono H, Yao K, Fujishiro M. et al. Guidelines for endoscopic submucosal dissection and endoscopic mucosal resection for early gastric cancer (second edition). Dig Endosc 2021; 33: 4-20
  • 2 Shin DW, Hwang HY, Jeon SW. Comparison of endoscopic submucosal dissection and surgery for differentiated type early gastric cancer within the expanded criteria. Clinical Endoscopy 2017; 50: 170-178
  • 3 Libânio D, Braga V, Ferraz S. et al. Prospective comparative study of endoscopic submucosal dissection and gastrectomy for early neoplastic lesions including patients' perspectives. Endoscopy 2019; 51: 30-39
  • 4 Nishida T, Kato M, Yoshio T. et al. Endoscopic submucosal dissection in early gastric cancer in elderly patients and comorbid conditions. World J Gastrointest Endosc 2015; 7: 524-531
  • 5 Kim BJ, Chang TH, Kim JJ. et al. Efficacy and safety of endoscopic submucosal dissection for early gastric cancer in patients with comorbid diseases. Gut Liver 2010; 4: 186-191
  • 6 Man-i M, Morita Y, Fujita T. et al. Endoscopic submucosal dissection for gastric neoplasm in patients with co-morbidities categorized according to the ASA Physical Status Classification. Gastric Cancer 2013; 16: 56-66
  • 7 Messer J, Reitman D, Sacks HS. et al. Association of adrenocorticosteroid therapy and peptic-ulcer disease. N Engl J Med 1983; 309: 21-24
  • 8 Piper JM, Ray WA, Daugherty JR. et al. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991; 114: 735-740
  • 9 Garb AE, Soule EH, Bartholomew LG. et al. Steroid-induced gastric ulcer. A clinicopathologic study. Arch Intern Med 1965; 116: 899-906
  • 10 Narum S, Westergren T, Klemp M. Corticosteroids and risk of gastrointestinal bleeding: a systematic review and meta-analysis. BMJ Open 2014; 4: e004587
  • 11 Yamamoto S, Kinugasa H, Yamasaki Y. et al. Fever and electrocoagulation syndrome after colorectal endoscopic submucosal dissection for patients with immunosuppressants and steroids. DEN Open 2022; 2: e83
  • 12 Koppie TM, Serio AM, Vickers AJ. et al. Age-adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer. Cancer 2008; 112: 2384-2392
  • 13 Austin PC. Statistical criteria for selecting the optimal number of untreated subjects matched to each treated subject when using many-to-one matching on the propensity score. Am J Epidemiol 2010; 172: 1092-1097
  • 14 Rubin DB. Matched sampling for causal effects: The use of matched sampling and regression adjustment to remove bias in observational studies. Biometrics 1973; 29: 185
  • 15 Shi X, Li R, Shi X. et al. The impact of the age-adjusted Charlson comorbidity index as a prognostic factor in patients with early gastric cancer after endoscopic submucosal dissection. Scand J Gastroenterol 2025; 60: 136-142
  • 16 Libânio D, Costa MN, Pimentel-Nunes P. et al. Risk factors for bleeding after gastric endoscopic submucosal dissection: a systematic review and meta-analysis. Gastrointest Endosc 2016; 84: 572-586
  • 17 Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant 2013; 48: 452-458
  • 18 Jung DH, Youn YH, Kim JH. et al. Factors influencing development of pain after gastric endoscopic submucosal dissection: a randomized controlled trial. Endoscopy 2015; 47: 1119-1123
  • 19 Slominski AT, Zmijewski MA. Glucocorticoids Inhibit Wound Healing: Novel Mechanism of Action. J Invest Dermatol 2017; 137: 1012-1014
  • 20 Kato M, Kaise M, Obata T. et al. Bacteremia and endotoxemia after endoscopic submucosal dissection for gastric neoplasia: pilot study. Gastric Cancer 2012; 15: 15-20
  • 21 Itaba S, Iboshi Y, Nakamura K. et al. Low-frequency of bacteremia after endoscopic submucosal dissection of the stomach. Dig Endosc 2011; 23: 69-72
  • 22 Lai Y, Zhang Q, Pan X. et al. Antibiotics for fever in patients without perforation after gastric endoscopic submucosal dissection and endoscopic submucosal excavation may be unnecessary: a propensity score-matching analysis. BMC Gastroenterol 2021; 21: 64
  • 23 Lin E, Calvano SE, Lowry SF. Inflammatory cytokines and cell response in surgery. Surgery 2000; 127: 117-126
  • 24 Yoshii S, Yamada T, Yamaguchi S. et al. Efficacy of vonoprazan for the prevention of bleeding after gastric endoscopic submucosal dissection with continuous use of antiplatelet agents. Endosc Int Open 2020; 8: E481-E487
  • 25 Takimoto K, Hagiwara A. Filling and shielding for postoperative gastric perforations of endoscopic submucosal dissection using polyglycolic acid sheets and fibrin glue. Endosc Int Open 2016; 4: E661-664
  • 26 Choi HS, Kim KO, Chun HJ. et al. The efficacy of transdermal fentanyl for pain relief after endoscopic submucosal dissection: a prospective, randomised controlled trial. Dig Liver Dis 2012; 44: 925-929
  • 27 Lai Y, Zhang Q, Liao F. et al. Incidence and risk factors for fever after endoscopic submucosal dissection and its derivative technology for gastric lesions. Heliyon 2024; 10: e25748
  • 28 Nomura T, Sugimoto S, Temma T. et al. Suturing techniques with endoscopic clips and special devices after endoscopic resection. Dig Endosc 2023; 35: 287-301